Clinical benefit of treatment after trastuzumab emtansine for HER2-positive metastatic breast cancer: a real-world multi-centre cohort study in Japan (WJOG12519B)

BACKGROUND: Trastuzumab emtansine (T-DM1) treatment for human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer after taxane with trastuzumab and pertuzumab is standard therapy. However, treatment strategies beyond T-DM1 are still in development with insufficient evidence o...

Descripción completa

Detalles Bibliográficos
Autores principales: Yokoe, Takamichi, Kurozumi, Sasagu, Nozawa, Kazuki, Ozaki, Yukinori, Maeda, Tetsuyo, Yazaki, Shu, Onishi, Mai, Fujimoto, Akihiro, Nakayama, Sayuka, Tsuboguchi, Yuko, Iwasa, Tsutomu, Sakai, Hitomi, Ogata, Misato, Terada, Mitsuo, Nishimura, Meiko, Onoe, Takuma, Masuda, Jun, Kurikawa, Michiko, Isaka, Hirotsugu, Hagio, Kanako, Shimomura, Akihiko, Okumura, Yuta, Futamura, Manabu, Shimokawa, Mototsugu, Takano, Toshimi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Singapore 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8064974/
https://www.ncbi.nlm.nih.gov/pubmed/33389616
http://dx.doi.org/10.1007/s12282-020-01192-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8064974/
https://www.ncbi.nlm.nih.gov/pubmed/33389616
http://dx.doi.org/10.1007/s12282-020-01192-y

Ejemplares similares